Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Leukemia

Free Subscription Articles published in Leukemia Retrieve available abstracts of 287 articles: HTML format Text format

Single Articles

January 2019
1. LOPEZ-MILLAN B, Sanchez-Martinez D, Roca-Ho H, Gutierrez-Aguera F, et al
   NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia.
   Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0353.
   PubMed     Text format     Abstract available
   
   
   
2. JAWHAR M, Dohner K, Kreil S, Schwaab J, et al
   KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis.
   Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0346.
   PubMed     Text format     Abstract available
   
   
   
3. REDA G, Cassin R, Gentile M, Mauro FR, et al
   IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia.
   Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0344.
   PubMed     Text format    
   
   
   
4. OZTURK S, Roessner PM, Schulze-Edinghausen L, Yazdanparast H, et al
   Rejection of adoptively transferred Emicro-TCL1 chronic lymphocytic leukemia cells in C57BL/6 substrains or knockout mouse lines.
   Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0332.
   PubMed     Text format    
   
   
   
5. HOANG VT, Verma D, Godavarthy PS, Llavona P, et al
   The transcriptional regulator FUBP1 influences disease outcome in murine and human myeloid leukemia.
   Leukemia. 2019 Jan 11. pii: 10.1038/s41375-018-0358.
   PubMed     Text format     Abstract available
   
   
   
6. GOUNARI M, Ntoufa S, Gerousi M, Vilia MG, et al
   Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment.
   Leukemia. 2019 Jan 3. pii: 10.1038/s41375-018-0335.
   PubMed     Text format    
   
   
   December 2018
7. ZHAO J, Liang JW, Xue HL, Shen SH, et al
   The genetics and clinical characteristics of children morphologically diagnosed as acute promyelocytic leukemia.
   Leukemia. 2018 Dec 21. pii: 10.1038/s41375-018-0338.
   PubMed     Text format     Abstract available
   
   
   
8. VELAZQUEZ-AVILA M, Balandran JC, Ramirez-Ramirez D, Velazquez-Avila M, et al
   High cortactin expression in B-cell acute lymphoblastic leukemia is associated with increased transendothelial migration and bone marrow relapse.
   Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0333.
   PubMed     Text format     Abstract available
   
   
   
9. SCHETELIG J, de Wreede LC, van Gelder M, Koster L, et al
   Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.
   Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0302.
   PubMed     Text format     Abstract available
   
   
   
10. EFFICACE F, Breccia M, Avvisati G, Cottone F, et al
    Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0325.
    PubMed     Text format     Abstract available
    
    
    
11. BORGA C, Foster CA, Iyer S, Garcia SP, et al
    Molecularly distinct models of zebrafish Myc-induced B cell leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0328.
    PubMed     Text format    
    
    
    
12. HANNA BS, Roessner PM, Scheffold A, Jebaraj BMC, et al
    PI3Kdelta inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 20. pii: 10.1038/s41375-018-0318.
    PubMed     Text format     Abstract available
    
    
    
13. VON TRESCKOW J, Cramer P, Bahlo J, Robrecht S, et al
    CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0313.
    PubMed     Text format     Abstract available
    
    
    
14. KIVIOJA JL, Thanasopoulou A, Kumar A, Kontro M, et al
    Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0327.
    PubMed     Text format     Abstract available
    
    
    
15. REEDIJK AMJ, Klein K, Coebergh JWW, Kremer LC, et al
    Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0314.
    PubMed     Text format     Abstract available
    
    
    
16. HASAN MK, Rassenti L, Widhopf GF 2nd, Yu J, et al
    Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Dec 19. pii: 10.1038/s41375-018-0306.
    PubMed     Text format     Abstract available
    
    
    
17. CORTES JE, Heidel FH, Hellmann A, Fiedler W, et al
    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0312.
    PubMed     Text format     Abstract available
    
    
    
18. PARK JH, Woo YM, Youm EM, Hamad N, et al
    HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0321.
    PubMed     Text format     Abstract available
    
    
    
19. TEN HACKEN E, Gounari M, Ghia P, Burger JA, et al
    The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia.
    Leukemia. 2018 Dec 16. pii: 10.1038/s41375-018-0303.
    PubMed     Text format     Abstract available
    
    
    
20. MODVIG S, Madsen HO, Siitonen SM, Rosthoj S, et al
    Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 14. pii: 10.1038/s41375-018-0307.
    PubMed     Text format     Abstract available
    
    
    
21. SCHERR M, Kirchhoff H, Battmer K, Wohlan K, et al
    Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0315.
    PubMed     Text format     Abstract available
    
    
    
22. ANDERSEN MA, Moser CE, Lundgren J, Niemann CU, et al
    Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study.
    Leukemia. 2018 Dec 13. pii: 10.1038/s41375-018-0316.
    PubMed     Text format     Abstract available
    
    
    
23. ZEIJLEMAKER W, Grob T, Meijer R, Hanekamp D, et al
    CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia.
    Leukemia. 2018 Dec 12. pii: 10.1038/s41375-018-0326.
    PubMed     Text format     Abstract available
    
    
    
24. HU X, Xu S, Chen Y, Gao Z, et al
    Depletion of Ars2 inhibits cell proliferation and leukemogenesis in acute myeloid leukemia by modulating the miR-6734-3p/p27 axis.
    Leukemia. 2018 Dec 5. pii: 10.1038/s41375-018-0301.
    PubMed     Text format     Abstract available
    
    
    November 2018
25. BLAGITKO-DORFS N, Schlosser P, Greve G, Pfeifer D, et al
    Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
    Leukemia. 2018 Nov 23. pii: 10.1038/s41375-018-0293.
    PubMed     Text format     Abstract available
    
    
    October 2018
26. CAESER R, Collord G, Yao WQ, Chen Z, et al
    Targeting MEK in vemurafenib-resistant hairy cell leukemia.
    Leukemia. 2018 Oct 19. pii: 10.1038/s41375-018-0270.
    PubMed     Text format    
    
    
    
27. KRAFT B, Lombard J, Kirsch M, Wuchter P, et al
    SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia.
    Leukemia. 2018 Oct 15. pii: 10.1038/s41375-018-0287.
    PubMed     Text format    
    
    
    
28. FRASER G, Cramer P, Demirkan F, Silva RS, et al
    Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0276.
    PubMed     Text format     Abstract available
    
    
    
29. OTHUS M, Sekeres MA, Nand S, Garcia-Manero G, et al
    Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0275.
    PubMed     Text format     Abstract available
    
    
    
30. OTHUS M, Estey EH, Garcia-Manero G, Wood BL, et al
    Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0274.
    PubMed     Text format    
    
    
    
31. ROSS DM, Pagani IS, Shanmuganathan N, Kok CH, et al
    Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells.
    Leukemia. 2018 Oct 12. pii: 10.1038/s41375-018-0264.
    PubMed     Text format     Abstract available
    
    
    
32. MANSO BA, Zhang H, Mikkelson MG, Gwin KA, et al
    Bone marrow hematopoietic dysfunction in untreated chronic lymphocytic leukemia patients.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0280.
    PubMed     Text format     Abstract available
    
    
    
33. YAN B, Chen Q, Shimada K, Tang M, et al
    Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0279.
    PubMed     Text format     Abstract available
    
    
    
34. WALKER CJ, Oakes CC, Genutis LK, Giacopelli B, et al
    Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA.
    Leukemia. 2018 Oct 5. pii: 10.1038/s41375-018-0281.
    PubMed     Text format    
    
    
    
35. BRAESS J, Amler S, Kreuzer KA, Spiekermann K, et al
    Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0268.
    PubMed     Text format     Abstract available
    
    
    
36. DOHNER H, Dolnik A, Tang L, Seymour JF, et al
    Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0257.
    PubMed     Text format     Abstract available
    
    
    
37. VANDEPOELE K, Van der Meulen J, Denys B
    The NF1 hotspot in acute myeloid leukemia: what's in a name?
    Leukemia. 2018 Oct 1. pii: 10.1038/s41375-018-0266.
    PubMed     Text format    
    
    
    September 2018
38. BHOJWANI D, Sposto R, Shah NN, Rodriguez V, et al
    Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0265.
    PubMed     Text format     Abstract available
    
    
    
39. HANNA BS, Roessner PM, Yazdanparast H, Colomer D, et al
    Control of chronic lymphocytic leukemia development by clonally-expanded CD8(+) T-cells that undergo functional exhaustion in secondary lymphoid tissues.
    Leukemia. 2018 Sep 28. pii: 10.1038/s41375-018-0250.
    PubMed     Text format     Abstract available
    
    
    
40. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
    Correction: Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0237.
    PubMed     Text format     Abstract available
    
    
    
41. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
    Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Sep 19. pii: 10.1038/s41375-018-0241.
    PubMed     Text format     Abstract available
    
    
    
42. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
    Correction: NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
    Leukemia. 2018 Sep 14. pii: 10.1038/s41375-018-0236.
    PubMed     Text format     Abstract available
    
    
    
43. KLUPSCH K, Baeriswyl V, Scholz R, Dannenberg J, et al
    COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia.
    Leukemia. 2018 Sep 11. pii: 10.1038/s41375-018-0249.
    PubMed     Text format    
    
    
    
44. MOUJALLED DM, Pomilio G, Ghiurau C, Ivey A, et al
    Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0261.
    PubMed     Text format     Abstract available
    
    
    
45. AGHEL N, Delgado DH, Lipton JH
    Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
    Leukemia. 2018 Sep 10. pii: 10.1038/s41375-018-0247.
    PubMed     Text format     Abstract available
    
    
    August 2018
46. TAKESHITA A, Asou N, Atsuta Y, Sakura T, et al
    Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.
    Leukemia. 2018 Aug 9. pii: 10.1038/s41375-018-0233.
    PubMed     Text format     Abstract available
    
    
    
47. DUPLOYEZ N, Marceau-Renaut A, Villenet C, Petit A, et al
    The stem cell-associated gene expression signature allows risk stratification in pediatric acute myeloid leukemia.
    Leukemia. 2018 Aug 8. pii: 10.1038/s41375-018-0227.
    PubMed     Text format     Abstract available
    
    
    
48. PATNAIK MM, Tefferi A, Garcia-Manero G
    Blast-phase chronic myelomonocytic leukemia: more than just semantics.
    Leukemia. 2018 Aug 7. pii: 10.1038/s41375-018-0228.
    PubMed     Text format    
    
    
    
49. KURTZ SE, Eide CA, Kaempf A, Mori M, et al
    Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.
    Leukemia. 2018 Aug 6. pii: 10.1038/s41375-018-0225.
    PubMed     Text format    
    
    
    July 2018
50. LEEKSMA AC, Taylor J, Wu B, Gardner JR, et al
    Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
    Leukemia. 2018 Jul 23. pii: 10.1038/s41375-018-0215.
    PubMed     Text format     Abstract available
    
    
    
51. KREITMAN RJ, Dearden C, Zinzani PL, Delgado J, et al
    Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.
    Leukemia. 2018 Jul 20. pii: 10.1038/s41375-018-0210.
    PubMed     Text format     Abstract available
    
    
    
52. ALDOSS I, Capelletti M, Park J, Pistofidis RS, et al
    Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0213.
    PubMed     Text format     Abstract available
    
    
    
53. CICCONI L, Fenaux P, Kantarjian H, Tallman M, et al
    Molecular remission as a therapeutic objective in acute promyelocytic leukemia.
    Leukemia. 2018 Jul 19. pii: 10.1038/s41375-018-0219.
    PubMed     Text format     Abstract available
    
    
    
54. LI Z, He S, Look AT
    The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
    Leukemia. 2018 Jul 15. pii: 10.1038/s41375-018-0201.
    PubMed     Text format    
    
    
    
55. L'ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
    Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
    Leukemia. 2018 Jul 9. pii: 10.1038/s41375-018-0177.
    PubMed     Text format     Abstract available
    
    
    
56. STUDD JB, Yang M, Li Z, Vijayakrishnan J, et al
    Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism.
    Leukemia. 2018 Jul 6. pii: 10.1038/s41375-018-0184.
    PubMed     Text format     Abstract available
    
    
    
57. LUNDIN-STROM KB, Biloglav A, Lilljebjorn H, Rissler M, et al
    Whole-exome sequencing exploration of acquired uniparental disomies in B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Jul 2. pii: 10.1038/s41375-018-0191.
    PubMed     Text format    
    
    
    June 2018
58. VICENTE-DUENAS C, Gonzalez-Herrero I, Sehgal L, Garcia-Ramirez I, et al
    Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0192.
    PubMed     Text format    
    
    
    
59. MARGOLSKEE E
    So-called "blast phase" of chronic myelomonocytic leukemia: a plea for uniform terminology.
    Leukemia. 2018 Jun 28. pii: 10.1038/s41375-018-0186.
    PubMed     Text format    
    
    
    
60. BOND J, Labis E, Marceau-Renaut A, Duployez N, et al
    Polycomb repressive complex 2 haploinsufficiency identifies a high-risk subgroup of pediatric acute myeloid leukemia.
    Leukemia. 2018 Jun 27. pii: 10.1038/s41375-018-0187.
    PubMed     Text format    
    
    
    
61. HOLMQVIST AS, Chen Y, Wu J, Kung M, et al
    Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2.
    Leukemia. 2018 Jun 26. pii: 10.1038/s41375-018-0171.
    PubMed     Text format    
    
    
    
62. CRIADO I, Blanco E, Rodriguez-Caballero A, Alcoceba M, et al
    Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.
    Leukemia. 2018 Jun 21. pii: 10.1038/s41375-018-0164.
    PubMed     Text format    
    
    
    
63. SUTTORP M, Schulze P, Glauche I, Gohring G, et al
    Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0179.
    PubMed     Text format     Abstract available
    
    
    
64. GEBHARD C, Glatz D, Schwarzfischer L, Wimmer J, et al
    Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association.
    Leukemia. 2018 Jun 20. pii: 10.1038/s41375-018-0165.
    PubMed     Text format     Abstract available
    
    
    
65. ERNST T, Busch M, Rinke J, Ernst J, et al
    Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia.
    Leukemia. 2018 Jun 13. pii: 10.1038/s41375-018-0157.
    PubMed     Text format    
    
    
    
66. BODDU P, Gurguis C, Sanford D, Cortes J, et al
    Response kinetics and factors predicting survival in core-binding factor leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0158.
    PubMed     Text format    
    
    
    
67. BOUDREAUX SP, Duren RP, Call SG, Nguyen L, et al
    Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0174.
    PubMed     Text format     Abstract available
    
    
    
68. TASIAN SK, Casas JA, Posocco D, Gandre-Babbe S, et al
    Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0169.
    PubMed     Text format     Abstract available
    
    
    
69. TIMILSHINA N, Breunis H, Tomlinson GA, Brandwein JM, et al
    Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0162.
    PubMed     Text format     Abstract available
    
    
    
70. BARGHOUT SH, Patel PS, Wang X, Xu GW, et al
    Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
    Leukemia. 2018 Jun 8. pii: 10.1038/s41375-018-0167.
    PubMed     Text format     Abstract available
    
    
    
71. EISFELD AK, Kohlschmidt J, Mrozek K, Mims A, et al
    NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
    Leukemia. 2018 Jun 5. pii: 10.1038/s41375-018-0147.
    PubMed     Text format     Abstract available
    
    
    May 2018
72. CHEUNG LC, Tickner J, Hughes AM, Skut P, et al
    New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
    Leukemia. 2018 May 8. pii: 10.1038/s41375-018-0144.
    PubMed     Text format     Abstract available
    
    
    April 2018
73. PATNAIK MM, Pierola AA, Vallapureddy R, Yalniz FF, et al
    Blast phase chronic myelomonocytic leukemia: Mayo-MDACC collaborative study of 171 cases.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0143.
    PubMed     Text format    
    
    
    
74. HUITING LN, Samaha Y, Zhang GL, Roderick JE, et al
    UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein response.
    Leukemia. 2018 Apr 25. pii: 10.1038/s41375-018-0141.
    PubMed     Text format     Abstract available
    
    
    
75. XIAO W, Rampal R, Zhang Y, Cimera R, et al
    JAK/MAP kinase pathway activation and TP53 mutations in acute leukemia with megakaryocytic and erythroid differentiation.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0145.
    PubMed     Text format    
    
    
    
76. KAYSER S, Schlenk RF, Platzbecker U
    Management of patients with acute promyelocytic leukemia.
    Leukemia. 2018 Apr 24. pii: 10.1038/s41375-018-0139.
    PubMed     Text format     Abstract available
    
    
    
77. GARCIA EG, Iyer S, Garcia SP, Loontiens S, et al
    Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0130.
    PubMed     Text format    
    
    
    
78. RENNEVILLE A, Attias P, Thomas X, Bally C, et al
    Genetic analysis of therapy-related myeloid neoplasms occurring after intensive treatment for acute promyelocytic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0137.
    PubMed     Text format    
    
    
    
79. DE BIE J, Demeyer S, Alberti-Servera L, Geerdens E, et al
    Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Apr 18. pii: 10.1038/s41375-018-0127.
    PubMed     Text format     Abstract available
    
    
    
80. PASCHKA P, Schlenk RF, Weber D, Benner A, et al
    Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0129.
    PubMed     Text format     Abstract available
    
    
    
81. STUDENCKA-TURSKI M, Maubach G, Feige MH, Naumann M, et al
    Constitutive activation of nuclear factor kappa B-inducing kinase counteracts apoptosis in cells with rearranged mixed lineage leukemia gene.
    Leukemia. 2018 Apr 17. pii: 10.1038/s41375-018-0128.
    PubMed     Text format    
    
    
    
82. WARTIOVAARA-KAUTTO U, Hirvonen EAM, Pitkanen E, Heckman C, et al
    Germline alterations in a consecutive series of acute myeloid leukemia.
    Leukemia. 2018 Apr 10. pii: 10.1038/s41375-018-0049.
    PubMed     Text format    
    
    
    
83. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
    Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
    Leukemia. 2018 Apr 7. pii: 10.1038/s41375-018-0032.
    PubMed     Text format    
    
    
    
84. HU T, Wu Q, Chong Y, Qin H, et al
    FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0124.
    PubMed     Text format     Abstract available
    
    
    
85. PATNAIK MM, Rangit Vallapureddy, Lasho TL, Hoversten KP, et al
    A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone.
    Leukemia. 2018 Apr 2. pii: 10.1038/s41375-018-0121.
    PubMed     Text format    
    
    
    March 2018
86. HOSSEINI MM, Kurtz SE, Abdelhamed S, Mahmood S, et al
    Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
    Leukemia. 2018 Mar 29. pii: 10.1038/s41375-018-0112.
    PubMed     Text format     Abstract available
    
    
    
87. THAN H, Qiao Y, Huang X, Yan D, et al
    Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0050.
    PubMed     Text format    
    
    
    
88. HOJJAT-FARSANGI M, Daneshmanesh AH, Khan AS, Shetye J, et al
    First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells.
    Leukemia. 2018 Mar 27. pii: 10.1038/s41375-018-0113.
    PubMed     Text format    
    
    
    
89. THI NGOC PC, Tan SH, Tan TK, Chan MM, et al
    Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0110.
    PubMed     Text format     Abstract available
    
    
    
90. GHIA P, Rawstron A
    Minimal residual disease analysis in chronic lymphocytic leukemia: a way for achieving more personalized treatments.
    Leukemia. 2018 Mar 26. pii: 10.1038/s41375-018-0109.
    PubMed     Text format     Abstract available
    
    
    
91. KUCHENBAUER F, Buske C
    Revisiting thrombocytopenia in acute promyelocytic leukemia.
    Leukemia. 2018 Mar 23. pii: 10.1038/s41375-018-0105.
    PubMed     Text format    
    
    
    
92. RUDAT S, Pfaus A, Cheng YY, Holtmann J, et al
    RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.
    Leukemia. 2018 Mar 22. pii: 10.1038/s41375-018-0102.
    PubMed     Text format     Abstract available
    
    
    
93. GENTILE M, Shanafelt TD, Reda G, Mauro FR, et al
    Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0100.
    PubMed     Text format    
    
    
    
94. BURNS MA, Liao ZW, Yamagata N, Pouliot GP, et al
    Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 20. pii: 10.1038/s41375-018-0097.
    PubMed     Text format     Abstract available
    
    
    
95. SUN W, Malvar J, Sposto R, Verma A, et al
    Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.
    Leukemia. 2018 Mar 15. pii: 10.1038/s41375-018-0094.
    PubMed     Text format     Abstract available
    
    
    
96. QIN YZ, Huang XJ, Zhu HH
    Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Leukemia. 2018 Mar 14. pii: 10.1038/s41375-018-0095.
    PubMed     Text format    
    
    
    
97. GUNNARSSON R, Dilorenzo S, Lundin-Strom KB, Olsson L, et al
    Mutation, methylation, and gene expression profiles in dup(1q)-positive pediatric B-cell precursor acute lymphoblastic leukemia.
    Leukemia. 2018 Mar 12. pii: 10.1038/s41375-018-0092.
    PubMed     Text format     Abstract available
    
    
    
98. KELLY AD, Madzo J, Madireddi P, Kropf P, et al
    Demethylator phenotypes in acute myeloid leukemia.
    Leukemia. 2018 Mar 7. pii: 10.1038/s41375-018-0084.
    PubMed     Text format     Abstract available
    
    
    February 2018
99. TAWANA K, Drazer MW, Churpek JE
    Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?
    Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0051.
    PubMed     Text format     Abstract available
    
    
    
100. MARUFFI M, Sposto R, Oberley MJ, Kysh L, et al
     Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis.
     Leukemia. 2018 Feb 27. pii: 10.1038/s41375-018-0058.
     PubMed     Text format     Abstract available
     
     
     
101. SAUSSELE S, Hehlmann R, Fabarius A, Jeromin S, et al
     Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.
     Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0055.
     PubMed     Text format     Abstract available
     
     
     
102. ALI A, Penneroux J, Dal Bello R Jr, Masse A, et al
     Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia.
     Leukemia. 2018 Feb 26. pii: 10.1038/s41375-018-0076.
     PubMed     Text format    
     
     
     
103. PETROV JC, Wada M, Pinz KG, Yan LE, et al
     Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.
     Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0075.
     PubMed     Text format     Abstract available
     
     
     
104. HNIZDA A, Fabry M, Moriyama T, Pachl P, et al
     Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
     Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0073.
     PubMed     Text format     Abstract available
     
     
     
105. EISFELD AK, Kohlschmidt J, Mrozek K, Blachly JS, et al
     Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies.
     Leukemia. 2018 Feb 25. pii: 10.1038/s41375-018-0068.
     PubMed     Text format     Abstract available
     
     
     
106. BICCLER JL, Ostgard LSG, Severinsen MT, Marcher CW, et al
     Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study.
     Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0054.
     PubMed     Text format    
     
     
     
107. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
     Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
     Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0034.
     PubMed     Text format     Abstract available
     
     
     
108. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
     Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).
     Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0039.
     PubMed     Text format     Abstract available
     
     
     
109. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
     Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
     Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0035.
     PubMed     Text format     Abstract available
     
     
     
110. LAVALLEE VP, Chagraoui J, MacRae T, Marquis M, et al
     Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin.
     Leukemia. 2018 Feb 23. pii: 10.1038/s41375-018-0069.
     PubMed     Text format     Abstract available
     
     
     
111. DAVER N, Boddu P, Garcia-Manero G, Yadav SS, et al
     Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
     Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0070.
     PubMed     Text format     Abstract available
     
     
     
112. L ABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
     MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.
     Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0033.
     PubMed     Text format     Abstract available
     
     
     
113. RASCHE M, Zimmermann M, Borschel L, Bourquin JP, et al
     Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
     Leukemia. 2018 Feb 22. pii: 10.1038/s41375-018-0071.
     PubMed     Text format     Abstract available
     
     
     
114. STRATI P, Ferrajoli A, Wierda WG, Jain N, et al
     Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia.
     Leukemia. 2018 Feb 20. pii: 10.1038/s41375-018-0059.
     PubMed     Text format    
     
     
     
115. CRAMER SD, Hixon JA, Andrews C, Porter RJ, et al
     Mutant IL-7Ralpha and mutant NRas are sufficient to induce murine T cell acute lymphoblastic leukemia.
     Leukemia. 2018 Feb 15. pii: 10.1038/s41375-017-0001.
     PubMed     Text format    
     
     
     
116. SUAREZ-GONZALEZ J, Martinez-Laperche C, Martinez N, Rodriguez-Macias G, et al
     Whole-exome sequencing reveals acquisition of mutations leading to the onset of donor cell leukemia after hematopoietic transplantation: a model of leukemogenesis.
     Leukemia. 2018 Feb 5. pii: 10.1038/s41375-018-0042.
     PubMed     Text format    
     
     
     
117. PENG D, Wang H, Li L, Ma X, et al
     miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.
     Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0015.
     PubMed     Text format     Abstract available
     
     
     
118. LA STARZA R, Messina M, Gianfelici V, Pierini V, et al
     High PIM1 expression is a biomarker of T-cell acute lymphoblastic leukemia with JAK/STAT activation or t(6;7)(p21;q34)/TRB@-PIM1 rearrangement.
     Leukemia. 2018 Feb 2. pii: 10.1038/s41375-018-0031.
     PubMed     Text format    
     
     
     
119. WINGELHOFER B, Maurer B, Heyes EC, Cumaraswamy AA, et al
     Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
     Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0005.
     PubMed     Text format     Abstract available
     
     
     
120. MALCIKOVA J, Tausch E, Rossi D, Sutton LA, et al
     ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.
     Leukemia. 2018 Feb 2. pii: 10.1038/s41375-017-0007.
     PubMed     Text format     Abstract available
     
     
     
121. BALASUBRAMANIAN SK, Aly M, Nagata Y, Bat T, et al
     Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.
     Leukemia. 2018;32:550-553.
     PubMed     Text format    
     
     
     
122. KLYMENKO T, Bloehdorn J, Bahlo J, Robrecht S, et al
     Lamin B1 regulates somatic mutations and progression of B-cell malignancies.
     Leukemia. 2018;32:364-375.
     PubMed     Text format     Abstract available
     
     
     
123. STENGEL A, Kern W, Meggendorfer M, Nadarajah N, et al
     Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML.
     Leukemia. 2018;32:295-302.
     PubMed     Text format     Abstract available
     
     
     
124. KUBESOVA B, Pavlova S, Malcikova J, Kabathova J, et al
     Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.
     Leukemia. 2018;32:450-461.
     PubMed     Text format     Abstract available
     
     
     
125. DEANGELO DJ, George TI, Linder A, Langford C, et al
     Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.
     Leukemia. 2018;32:470-478.
     PubMed     Text format     Abstract available
     
     
     
126. LIU E, Tong Y, Dotti G, Shaim H, et al
     Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
     Leukemia. 2018;32:520-531.
     PubMed     Text format     Abstract available
     
     
     
127. MEYER C, Burmeister T, Groger D, Tsaur G, et al
     The MLL recombinome of acute leukemias in 2017.
     Leukemia. 2018;32:273-284.
     PubMed     Text format     Abstract available
     
     
     
128. GARRIDO CASTRO P, van Roon EHJ, Pinhancos SS, Trentin L, et al
     The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
     Leukemia. 2018;32:323-331.
     PubMed     Text format     Abstract available
     
     
     
129. KAUSHIK S, Liu F, Veazey KJ, Gao G, et al
     Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
     Leukemia. 2018;32:499-509.
     PubMed     Text format     Abstract available
     
     
     January 2018
130. SUN X, Ren Y, Gunawan S, Teng P, et al
     Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099.
     Leukemia. 2018 Jan 30. pii: 10.1038/s41375-018-0020.
     PubMed     Text format    
     
     
     
131. JO S, Lee JH, Mattei JJ, Barrett DM, et al
     Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
     Leukemia. 2018 Jan 5. pii: leu2017312. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
132. PIETTE C, Suciu S, Clappier E, Bertrand Y, et al
     Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials.
     Leukemia. 2018;32:244-248.
     PubMed     Text format    
     
     
     
133. BUONTEMPO F, McCubrey JA, Orsini E, Ruzzene M, et al
     Therapeutic targeting of CK2 in acute and chronic leukemias.
     Leukemia. 2018;32:1-10.
     PubMed     Text format     Abstract available
     
     
     
134. BRAZDILOVA K, Plevova K, Skuhrova Francova H, Kockova H, et al
     Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.
     Leukemia. 2018;32:234-236.
     PubMed     Text format    
     
     
     
135. BODDU P, Jorgensen J, Kantarjian H, Borthakur G, et al
     Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
     Leukemia. 2018;32:241-244.
     PubMed     Text format    
     
     
     
136. GU S, Sayad A, Chan G, Yang W, et al
     SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
     Leukemia. 2018;32:203-213.
     PubMed     Text format     Abstract available
     
     
     
137. MINGAY M, Chaturvedi A, Bilenky M, Cao Q, et al
     Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia.
     Leukemia. 2018;32:11-20.
     PubMed     Text format     Abstract available
     
     
     
138. GOLE B, Mian E, Rall M, Wiesmuller L, et al
     Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization.
     Leukemia. 2018;32:159-167.
     PubMed     Text format     Abstract available
     
     
     
139. BROWN JR, Hillmen P, O'Brien S, Barrientos JC, et al
     Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.
     Leukemia. 2018;32:83-91.
     PubMed     Text format     Abstract available
     
     
     
140. VILLARESE P, Lours C, Trinquand A, Le Noir S, et al
     TCRalpha rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome.
     Leukemia. 2018;32:61-71.
     PubMed     Text format     Abstract available
     
     
     
141. SUN L, Shi Y, Wang G, Wang X, et al
     PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
     Leukemia. 2018;32:184-193.
     PubMed     Text format     Abstract available
     
     
     
142. WELSH SJ, Churchman ML, Togni M, Mullighan CG, et al
     Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.
     Leukemia. 2018;32:38-48.
     PubMed     Text format     Abstract available
     
     
     December 2017
143. GUPTA S, Devidas M, Loh ML, Raetz EA, et al
     Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG).
     Leukemia. 2017 Dec 18. pii: leu2017341. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
144. BU J, Chen A, Yan X, He F, et al
     SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.
     Leukemia. 2017 Dec 18. pii: leu2017339. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
145. FONTANA MC, Marconi G, Feenstra JDM, Fonzi E, et al
     Chromothripsis in acute myeloid leukemia: Biological features and impact on survival.
     Leukemia. 2017 Dec 18. pii: leu2017351. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
146. ROTHENBERG-THURLEY M, Amler S, Goerlich D, Kohnke T, et al
     Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
     Leukemia. 2017 Dec 18. pii: leu2017350. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
147. CASADO P, Wilkes EH, Miraki-Moud F, Hadi MM, et al
     Proteomic and genomic integration identifies kinase and differentiation determinants of kinase inhibitor sensitivity in leukemia cells.
     Leukemia. 2017 Dec 12. pii: leu2017349. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
148. TIRADO-GONZALEZ I, Czlonka E, Nevmerzhitskaya A, Soetopo D, et al
     CRISPR/Cas9 edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.
     Leukemia. 2017 Dec 6. pii: leu2017346. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
149. DRIESSEN EMC, de Lorenzo P, Campbell M, Felice M, et al
     Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol.
     Leukemia. 2017;31:2854.
     PubMed     Text format     Abstract available
     
     
     
150. GRZES KM, Swamy M, Hukelmann JL, Emslie E, et al
     Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.
     Leukemia. 2017;31:2771-2779.
     PubMed     Text format     Abstract available
     
     
     
151. GARCIA-MANERO G, Sekeres MA, Egyed M, Breccia M, et al
     A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts.
     Leukemia. 2017;31:2799-2806.
     PubMed     Text format     Abstract available
     
     
     
152. TESIO M, Trinquand A, Ballerini P, Hypolite G, et al
     Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia.
     Leukemia. 2017;31:2594-2600.
     PubMed     Text format     Abstract available
     
     
     
153. ELDER A, Bomken S, Wilson I, Blair HJ, et al
     Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia.
     Leukemia. 2017;31:2577-2586.
     PubMed     Text format     Abstract available
     
     
     
154. DELGADO-MARTIN C, Meyer LK, Huang BJ, Shimano KA, et al
     JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias.
     Leukemia. 2017;31:2568-2576.
     PubMed     Text format     Abstract available
     
     
     
155. RASCHE M, von Neuhoff C, Dworzak M, Bourquin JP, et al
     Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.
     Leukemia. 2017;31:2807-2814.
     PubMed     Text format     Abstract available
     
     
     
156. ZHANG H, Reister Schultz A, Luty S, Rofelty A, et al
     Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations.
     Leukemia. 2017;31:2752-2760.
     PubMed     Text format     Abstract available
     
     
     
157. LYU Y, Lou J, Yang Y, Feng J, et al
     Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways.
     Leukemia. 2017;31:2543-2551.
     PubMed     Text format     Abstract available
     
     
     
158. YOKOTA A, Hirai H, Shoji T, Maekawa T, et al
     Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
     Leukemia. 2017;31:2742-2751.
     PubMed     Text format     Abstract available
     
     
     November 2017
159. LABBATE A, Tolomeo D, Cifola I, Severgnini M, et al
     MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.
     Leukemia. 2017 Nov 28. pii: leu2017337. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
160. NIMMAGADDA SC, Frey S, Edelmann B, Hellmich C, et al
     Bruton's Tyrosine Kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
     Leukemia. 2017 Nov 7. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
161. LHERMITTE L, Mejstrikova E, van der Sluijs-Gelling AJ, Grigore GE, et al
     Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia.
     Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
162. WALF-VORDERWULBECKE V, Pearce K, Brooks T, Hubank M, et al
     Targeting acute myeloid leukemia by drug-induced c-MYB degradation.
     Leukemia. 2017 Nov 1. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
163. HADZIJUSUFOVIC E, Albrecht-Schgoer K, Huber K, Hoermann G, et al
     Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
     Leukemia. 2017;31:2388-2397.
     PubMed     Text format     Abstract available
     
     
     
164. PULIKKAN JA, Tenen DG, Behre G
     C/EBPalpha deregulation as a paradigm for leukemogenesis.
     Leukemia. 2017;31:2279-2285.
     PubMed     Text format     Abstract available
     
     
     
165. LIU X, Rothe K, Yen R, Fruhstorfer C, et al
     A novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.
     Leukemia. 2017;31:2376-2387.
     PubMed     Text format     Abstract available
     
     
     
166. THIEL VN, Giaimo BD, Schwarz P, Soller K, et al
     Heterodimerization of AML1/ETO with CBFbeta is required for leukemogenesis but not for myeloproliferation.
     Leukemia. 2017;31:2491-2502.
     PubMed     Text format     Abstract available
     
     
     
167. O'LEARY HA, Capitano M, Cooper S, Mantel C, et al
     DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.
     Leukemia. 2017;31:2468-2478.
     PubMed     Text format     Abstract available
     
     
     
168. HOWARD DR, Munir T, McParland L, Rawstron AC, et al
     Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.
     Leukemia. 2017;31:2416-2425.
     PubMed     Text format     Abstract available
     
     
     
169. SAVINO AM, Sarno J, Trentin L, Vieri M, et al
     The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
     Leukemia. 2017;31:2365-2375.
     PubMed     Text format     Abstract available
     
     
     
170. KRAMER AC, Kothari A, Wilson WC, Celik H, et al
     Dnmt3a regulates T-cell development and suppresses T-ALL transformation.
     Leukemia. 2017;31:2479-2490.
     PubMed     Text format     Abstract available
     
     
     
171. ABRAHAM M, Klein S, Bulvik B, Wald H, et al
     The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.
     Leukemia. 2017;31:2336-2346.
     PubMed     Text format     Abstract available
     
     
     
172. HA VL, Luong A, Li F, Casero D, et al
     The T-ALL related gene BCL11B regulates the initial stages of human T-cell differentiation.
     Leukemia. 2017;31:2503-2514.
     PubMed     Text format     Abstract available
     
     
     
173. DELL'AVERSANA C, Giorgio C, D'Amato L, Lania G, et al
     miR-194-5p/BCLAF1 deregulation in AML tumorigenesis.
     Leukemia. 2017;31:2315-2325.
     PubMed     Text format     Abstract available
     
     
     October 2017
174. SAID B, Gilles S, Weisdorf D, Rashidi A, et al
     The role of bone marrow morphology in the diagnosis of relapsed acute myeloid leukemia.
     Leukemia. 2017 Oct 31. doi: 10.1038/leu.2017.
     PubMed     Text format    
     
     
     
175. YAN F, Shen N, Pang JX, Zhao N, et al
     A vicious loop of fatty acid-binding protein 4 and DNA methyltransferase 1 promotes acute myeloid leukemia and acts as a therapeutic target.
     Leukemia. 2017 Oct 10. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
176. TOPP MS, Stelljes M, Zugmaier G, Barnette P, et al
     Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.
     Leukemia. 2017 Oct 9. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
177. JERCHEL IS, Hoogkamer AQ, Aries IM, Steeghs EMP, et al
     RAS pathway mutations as predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.
     Leukemia. 2017 Oct 3. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
178. LI Z, Abraham BJ, Berezovskaya A, Farah N, et al
     APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.
     Leukemia. 2017;31:2057-2064.
     PubMed     Text format     Abstract available
     
     
     
179. MUNIR T, Howard DR, McParland L, Pocock C, et al
     Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.
     Leukemia. 2017;31:2085-2093.
     PubMed     Text format     Abstract available
     
     
     
180. JU HQ, Zhan G, Huang A, Sun Y, et al
     ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
     Leukemia. 2017;31:2143-2150.
     PubMed     Text format     Abstract available
     
     
     
181. DUELL J, Dittrich M, Bedke T, Mueller T, et al
     Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL.
     Leukemia. 2017;31:2181-2190.
     PubMed     Text format     Abstract available
     
     
     
182. CHEN KH, Wada M, Pinz KG, Liu H, et al
     Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.
     Leukemia. 2017;31:2151-2160.
     PubMed     Text format     Abstract available
     
     
     September 2017
183. FUJITA S, Honma D, Adachi N, Araki K, et al
     Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
     Leukemia. 2017 Sep 27. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
184. PRIETO C, Lopez-Millan B, Roca-Ho H, Stam RW, et al
     NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL.
     Leukemia. 2017 Sep 25. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
185. BENEDETTI D, Tissino E, Pozzo F, Bittolo T, et al
     NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: Link between the NOTCH1 and the NF-kB pathways.
     Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
186. JO S, Lee JH, Mattei JJ, Barrett DM, et al
     Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia.
     Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
187. DEL GIUDICE I, Rigolin GM, Raponi S, Cafforio L, et al
     Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low and very-low risk genetic profile.
     Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
188. NADEU F, Clot G, Delgado J, Martin-Garcia D, et al
     Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia.
     Leukemia. 2017 Sep 19. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
189. HOSPITAL MA, Jacquel A, Mazed F, Saland E, et al
     RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.
     Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
190. SAKURA T, Hayakawa F, Sugiura I, Murayama T, et al
     High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: A phase III study by JALSG.
     Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
191. WAIBEL M, Vervoort SJ, Kong IY, Heinzel S, et al
     Epigenetic targeting of Notch1 driven transcription using the HDACi panobinostat is a potential therapy against T cell acute lymphoblastic leukemia.
     Leukemia. 2017 Sep 15. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
192. TAKAO S, Chien W, Madan V, Lin DC, et al
     Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.
     Leukemia. 2017 Sep 14. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
193. MARNETH AE, Prange KHM, Al Hinai ASA, Bergevoet SM, et al
     C-terminal BRE overexpression in 11q23-rearranged and t(8;16) acute myeloid leukemia is caused by intragenic transcription initiation.
     Leukemia. 2017 Sep 5. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
194. RINKE J, Muller JP, Blaess MF, Chase A, et al
     Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
     Leukemia. 2017;31:1936-1943.
     PubMed     Text format     Abstract available
     
     
     
195. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
     The clonal origins of leukemic progression of myelodysplasia.
     Leukemia. 2017;31:1928-1935.
     PubMed     Text format     Abstract available
     
     
     
196. SAENZ DT, Fiskus W, Qian Y, Manshouri T, et al
     Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells.
     Leukemia. 2017;31:1951-1961.
     PubMed     Text format     Abstract available
     
     
     
197. RONCHINI C, Brozzi A, Riva L, Luzi L, et al
     PML-RARA-associated cooperating mutations belong to a transcriptional network that is deregulated in myeloid leukemias.
     Leukemia. 2017;31:1975-1986.
     PubMed     Text format     Abstract available
     
     
     August 2017
198. DEGRYSE S, de Bock CE, Demeyer S, Govaerts I, et al
     Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
     Leukemia. 2017 Aug 30. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
199. JYOTSANA N, Sharma A, Chaturvedi A, Scherr M, et al
     RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.
     Leukemia. 2017 Aug 22. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
200. ZHAO L, Alkadi H, Kwon EM, Zhen T, et al
     The C-terminal multimerization domain is essential for leukemia development by CBFbeta-SMMHC in a mouse knockin model.
     Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
201. TOFT N, Birgens H, Abrahamsson J, Griskevicius L, et al
     Results of NOPHO ALL2008 treatment for patients 1-45 years with acute lymphoblastic leukemia.
     Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
202. PENA-MARTINEZ P, Eriksson M, Ramakrishnan R, Chapellier M, et al
     Interleukin 4 induces apoptosis of acute myeloid leukemia cells in a Stat6 dependent manner.
     Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
203. KUMAR B, Garcia M, Weng L, Jung X, et al
     Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.
     Leukemia. 2017 Aug 17. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
204. ARTESI M, Marcais A, Durkin K, Rosewick N, et al
     Monitoring molecular response in adult t-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality.
     Leukemia. 2017 Aug 16. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
205. HOECHSTETTER MA, Busch R, Eichhorst B, Buhler A, et al
     Early, risk-adapted treatment with fludarabine in binet stage a chronic lymphocytic leukemia patients: Results of the CLL1 trial of the German CLL study group.
     Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
206. HEHLMANN R, Lauseker M, Saussele S, Pfirrmann M, et al
     Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
     Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
207. REITER K, Polzer H, Krupka C, Maiser A, et al
     Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
     Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
208. MASCIARELLI S, Capuano E, Ottone T, Divona M, et al
     'Retinoic acid and arsenic trioxide sensitize acute promyelocytic leukemia cells to ER stress'.
     Leukemia. 2017 Aug 4. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
209. RAFIQ S, Purdon TJ, Daniyan AF, Koneru M, et al
     Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
     Leukemia. 2017;31:1788-1797.
     PubMed     Text format     Abstract available
     
     
     
210. DRENNAN S, D'Avola A, Gao Y, Weigel C, et al
     IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus.
     Leukemia. 2017;31:1686-1694.
     PubMed     Text format     Abstract available
     
     
     July 2017
211. KIM HG, LeGrand J, Swindle CS, Nick HJ, et al
     The assembly competence domain is essential for inv(16)-associated acute myeloid leukemia.
     Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
212. YIGIT B, Wang N, Chen SS, Chiorazzi N, et al
     Inhibition of Reactive oxygen species (ROS) limits expansion of chronic lymphocytic leukemia cells.
     Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
213. TEH TC, Nguyen NY, Moujalled DM, Segal D, et al
     Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1.
     Leukemia. 2017 Jul 28. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
214. GIRARDI T, Vereecke S, Sulima SO, Khan Y, et al
     The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling.
     Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
215. XIA F, Zhang Y, Xie L, Jiang H, et al
     B7-H4 enhances the differentiation of murine leukemia-initiating cells via the PTEN/AKT/RCOR2/RUNX1 pathways.
     Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
216. SOPPER S, Mustjoki S, Gjertsen BT, Giles F, et al
     NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.
     Leukemia. 2017 Jul 24. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
217. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
     Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.
     Leukemia. 2017 Jul 12. doi: 10.1038/leu.2017.
     PubMed     Text format    
     
     
     
218. BECK D, Thoms JAI, Palu C, Herold T, et al
     A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients.
     Leukemia. 2017 Jul 4. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
219. HOURIGAN CS, Gale RP, Gormley NJ, Ossenkoppele GJ, et al
     Measurable residual disease testing in acute myeloid leukaemia.
     Leukemia. 2017;31:1482-1490.
     PubMed     Text format     Abstract available
     
     
     
220. CUTLER JA, Tahir R, Sreenivasamurthy SK, Mitchell C, et al
     Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.
     Leukemia. 2017;31:1513-1524.
     PubMed     Text format     Abstract available
     
     
     
221. RIBEIRO ST, Tesio M, Ribot JC, Macintyre E, et al
     Casein kinase 2 controls the survival of normal thymic and leukemic gammadelta T cells via promotion of AKT signaling.
     Leukemia. 2017;31:1603-1610.
     PubMed     Text format     Abstract available
     
     
     June 2017
222. ANGENENDT L, Reuter S, Kentrup D, Benk AS, et al
     An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.
     Leukemia. 2017 Jun 30. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
223. YABE T, Azuma F, Kashiwase K, Matsumoto K, et al
     HLA-DPB1 mismatch induces a graft-versus-leukemia (GVL) effect without severe acute GVHD after single-unit umbilical cord blood transplantation.
     Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
224. TIAO G, Improgo MR, Kasar S, Poh W, et al
     Rare germline variants in ATM are associated with chronic lymphocytic leukemia.
     Leukemia. 2017 Jun 27. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
225. GAIDZIK VI, Weber D, Paschka P, Kaumanns A, et al
     DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.
     Leukemia. 2017 Jun 23. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
226. ZHANG Q, Ball MC, Zhao Y, Balasis M, et al
     Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.
     Leukemia. 2017 Jun 21. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
227. RIO-MACHIN A, Gomez-Lopez G, Munoz J, Garcia-Martinez F, et al
     The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia.
     Leukemia. 2017 Jun 20. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
228. GODWIN CD, Gale RP, Walter RB
     Gemtuzumab ozogamicin in acute myeloid leukemia.
     Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
229. SANTINI V, Allione B, Zini G, Gioia D, et al
     A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
     Leukemia. 2017 Jun 13. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
230. BURNS A, Alsolami R, Becq J, Timbs A, et al
     Whole genome sequencing of chronic lymphocytic leukemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups.
     Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
231. MARTINEZ-CUADRON D, Montesinos P, Vellenga E, Bernal T, et al
     Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy.
     Leukemia. 2017 Jun 6. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
232. PROMOD ST, Johnson DP, Bennett SE, Dennis EM, et al
     HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.
     Leukemia. 2017 Jun 5. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
233. HAHN M, Burckert JP, Luttenberger CA, Klebow S, et al
     Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-kappaB signaling.
     Leukemia. 2017 Jun 1. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
234. USTUN C, Giannotti F, Zhang MJ, Wang HL, et al
     Outcomes of UCB transplantation are comparable in FLT3+ AML: results of CIBMTR, EUROCORD and EBMT collaborative analysis.
     Leukemia. 2017;31:1408-1414.
     PubMed     Text format     Abstract available
     
     
     
235. HERNDON TM, Chen SS, Saba NS, Valdez J, et al
     Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood.
     Leukemia. 2017;31:1340-1347.
     PubMed     Text format     Abstract available
     
     
     
236. YAN F, Shen N, Pang JX, Zhang YW, et al
     Fatty acid-binding protein FABP4 mechanistically links obesity with aggressive AML by enhancing aberrant DNA methylation in AML cells.
     Leukemia. 2017;31:1434-1442.
     PubMed     Text format     Abstract available
     
     
     
237. CHENG G, Liu F, Asai T, Lai F, et al
     Loss of p300 accelerates MDS-associated leukemogenesis.
     Leukemia. 2017;31:1382-1390.
     PubMed     Text format     Abstract available
     
     
     
238. RODMAN C, Almeida-Porada G, George SK, Moon J, et al
     In vitro and in vivo assessment of direct effects of simulated solar and galactic cosmic radiation on human hematopoietic stem/progenitor cells.
     Leukemia. 2017;31:1398-1407.
     PubMed     Text format     Abstract available
     
     
     
239. CARTER MJ, Cox KL, Blakemore SJ, Turaj AH, et al
     PI3Kdelta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.
     Leukemia. 2017;31:1423-1433.
     PubMed     Text format     Abstract available
     
     
     May 2017
240. HALPERN AB, Othus M, Huebner EM, Buckley SA, et al
     Mitoxantrone, etoposide, and cytarabine (MEC) following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: A phase 1/2 study.
     Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
241. HA JS, Do YR, Ki CS, Lee C, et al
     Identification of a novel PML-RARG fusion in acute promyelocytic leukemia.
     Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
242. PATEL B, Przychodzen B, Thota S, Radivoyevitch T, et al
     Genomic determinants of chronic myelomonocytic leukemia.
     Leukemia. 2017 May 30. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
243. HEILMANN AM, Schrock AB, He J, Nahas M, et al
     Novel PDGFRB fusions in childhood B and T acute lymphoblastic leukemia.
     Leukemia. 2017 May 29. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
244. MA Z, Zhao X, Huang J, Jia X, et al
     A critical role of periostin in B-cell acute lymphoblastic leukemia.
     Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
245. BERNSON E, Hallner A, Sander FE, Wilsson O, et al
     Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
     Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
246. HINZE L, Moricke A, Zimmermann M, Junk S, et al
     Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
     Leukemia. 2017 May 22. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
247. CHEN L, Mao H, Zhang J, Chu J, et al
     Targeting FLT3 by chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
     Leukemia. 2017 May 12. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
248. PAN J, Yang J, Deng B, Zhao X, et al
     High efficacy and safety of low dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
     Leukemia. 2017 May 11. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
249. ROSSETTI C, Picardi E, Ye M, Camilli G, et al
     RNA editing signature during myeloid leukemia cell differentiation.
     Leukemia. 2017 May 9. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
250. HASAN K, Yu J, Chen L, Cui B, et al
     Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
     Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
251. YU J, Chen L, Chen Y, Hasan K, et al
     Wnt5a induces ROR1 to associate with 14-3-3zeta for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
     Leukemia. 2017 May 3. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
252. SLINGER E, Thijssen R, Kater AP, Eldering E, et al
     Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition.
     Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
253. LONG J, Fang WY, Chang L, Gao WH, et al
     Targeting HDAC3, new partner protein of AKT in the reversal of chemo-resistance in acute myeloid leukemia via DNA damage response.
     Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
254. GUNNARSSON N, Hoglund M, Stenke L, Sandin F, et al
     No increased prevalence of malignancies among first-degree relatives of 800 patients with chronic myeloid leukemia-a population-based study in Sweden.
     Leukemia. 2017 May 2. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
255. EIRING AM, Page BDG, Kraft IL, Mason CC, et al
     Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
     Leukemia. 2017;31:1253-1254.
     PubMed     Text format    
     
     
     
256. LEROY E, Constantinescu SN
     Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile janus kinase inhibition.
     Leukemia. 2017;31:1023-1038.
     PubMed     Text format     Abstract available
     
     
     
257. KAZIANKA L, Drucker C, Skrabs C, Thomas W, et al
     Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
     Leukemia. 2017;31:1117-1122.
     PubMed     Text format     Abstract available
     
     
     
258. MALANI D, Murumagi A, Yadav B, Kontro M, et al
     Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML.
     Leukemia. 2017;31:1187-1195.
     PubMed     Text format     Abstract available
     
     
     
259. LIU TH, Tang YJ, Huang Y, Wang L, et al
     Expression of the fetal hematopoiesis regulator FEV indicates leukemias of prenatal origin.
     Leukemia. 2017;31:1079-1086.
     PubMed     Text format     Abstract available
     
     
     April 2017
260. CAZZANIGA G, Bisanti L, Randi G, Deandrea S, et al
     Possible role of pandemic AH1N1 swine flu virus in a childhood leukemia cluster.
     Leukemia. 2017 Apr 27. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
261. ROSENQUIST R, Ghia P, Hadzidimitriou A, Sutton LA, et al
     Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: Updated eric recommendations.
     Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
262. MAEKAWA T, Osawa Y, Izumi T, Nagao S, et al
     Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
     Leukemia. 2017 Apr 25. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
263. KONGTIM P, Adekola K, Milton DR, Ramlal R, et al
     Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
     Leukemia. 2017 Apr 12. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
264. HAN SH, Kim SH, Kim HJ, Lee Y, et al
     Cobll1 is linked to drug resistance and blastic transformation in chronic myeloid leukemia.
     Leukemia. 2017 Apr 11. doi: 10.1038/leu.2017.
     PubMed     Text format    
     
     
     
265. JONES D, Woyach JA, Zhao W, Caruthers S, et al
     PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.
     Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
266. SILVA P, Neumann M, Schroeder MP, Vosberg S, et al
     Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape.
     Leukemia. 2017 Apr 3. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
267. HEATH EM, Chan SM, Minden MD, Murphy T, et al
     Biological and clinical consequences of NPM1 mutations in AML.
     Leukemia. 2017;31:798-807.
     PubMed     Text format     Abstract available
     
     
     
268. VALENT P, Sotlar K, Blatt K, Hartmann K, et al
     Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.
     Leukemia. 2017;31:788-797.
     PubMed     Text format     Abstract available
     
     
     
269. SCHUTZ C, Inselmann S, Sausslele S, Dietz CT, et al
     Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
     Leukemia. 2017;31:829-836.
     PubMed     Text format     Abstract available
     
     
     March 2017
270. HEROLD S, Kuhn M, Bonin MV, Stange T, et al
     Donor cell leukemia-Evidence for multiple pre-leukemic clones and parallel long term clonal evolution in donor and recipient.
     Leukemia. 2017 Mar 28. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
271. ANADON C, van Tetering G, Ferreira HJ, Moutinho C, et al
     Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.
     Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
272. COSSON A, Chapiro E, Bougacha N, Lambert J, et al
     Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: Analysis of the central role of XPO1.
     Leukemia. 2017 Mar 27. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
273. MONTALBAN-BRAVO G, Huang X, Naqvi K, Jabbour E, et al
     A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials.
     Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
     PubMed     Text format    
     
     
     
274. WALKER CJ, Eisfeld AK, Genutis LK, Bainazar M, et al
     No evidence for microsatellite instability in acute myeloid leukemia.
     Leukemia. 2017 Mar 24. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
275. KAYSER S, Krzykalla J, Elliott MA, Norsworthy K, et al
     Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide.
     Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
276. ZHOU H, Mak PY, Mu H, Mak DH, et al
     Combined inhibition of beta-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
     Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
277. EISFELD AK, Mrozek K, Kohlschmidt J, Nicolet D, et al
     The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia.
     Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
278. POZZO F, Bittolo T, Vendramini E, Bomben R, et al
     NOTCH1 mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin-1 and ribosome associated components.
     Leukemia. 2017 Mar 21. doi: 10.1038/leu.2017.
     PubMed     Text format     Abstract available
     
     
     
279. KOEFFLER HP, Leong G
     Preleukemia: one name, many meanings.
     Leukemia. 2017;31:534-542.
     PubMed     Text format     Abstract available
     
     
     
280. SAENZ DT, Fiskus W, Manshouri T, Rajapakshe K, et al
     BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
     Leukemia. 2017;31:678-687.
     PubMed     Text format     Abstract available
     
     
     
281. QAZILBASH MH, Wieder E, Thall PF, Wang X, et al
     PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.
     Leukemia. 2017;31:697-704.
     PubMed     Text format     Abstract available
     
     
     
282. STRUSKI S, Lagarde S, Bories P, Puiseux C, et al
     NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
     Leukemia. 2017;31:565-572.
     PubMed     Text format     Abstract available
     
     
     
283. STENGEL A, Kern W, Haferlach T, Meggendorfer M, et al
     The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases.
     Leukemia. 2017;31:705-711.
     PubMed     Text format     Abstract available
     
     
     
284. MCCRACKEN AN, McMonigle RJ, Tessier J, Fransson R, et al
     Phosphorylation of a constrained azacyclic FTY720 analog enhances anti-leukemic activity without inducing S1P receptor activation.
     Leukemia. 2017;31:669-677.
     PubMed     Text format     Abstract available
     
     
     
285. EDELMANN J, Tausch E, Landau DA, Robrecht S, et al
     Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial.
     Leukemia. 2017;31:734-738.
     PubMed     Text format    
     
     
     February 2017
286. MEDEIROS BC, Fathi AT, DiNardo CD, Pollyea DA, et al
     Isocitrate dehydrogenase mutations in myeloid malignancies.
     Leukemia. 2017;31:272-281.
     PubMed     Text format     Abstract available
     
     
     
287. BURNETT AK, Russell NH, Hills RK, Kell J, et al
     A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
     Leukemia. 2017;31:310-317.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: